CEP192

Across TCGA pan-cancer cohorts, CEP192 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CEP192 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CEP192 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CEP192 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where CEP192 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.757	0.440	.013	10	view →
CCRCC	OS	Tertile	All	1.000	0.568	.004	7	view →
PDAC	DFS	Tertile	IV	0.182	0.515	.024	3	view →
GBM	OS	Median	All	0.624	0.435	.022	2	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.341	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CEP192–LUAD (DFS)

Open the LUAD breakdown →